本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

La Jolla Pharmaceutical Company

6.22
0.0000
成交量:- -
成交額:166.46萬
市值:1.55億
市盈率:48.19
高:6.22
開:6.22
低:6.22
收:6.22
資料載入中...
2023/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/08/29

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2022/08/29

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/08/24

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/08/23

員工持股計劃

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2022/08/23

員工持股計劃

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2022/08/23

員工持股計劃

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2022/08/23

員工持股計劃

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2022/08/23

員工持股計劃

S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2022/08/22

重要事件披露

8-K - Current report
2022/08/22

交易所摘牌聲明

25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2022/08/15

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/07/12

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/07/11

重要事件披露

8-K - Current report
2022/07/11

企業合併公告

425 - Prospectuses and communications, business combinations
2022/05/16

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/05/02

[修訂]年度報告

10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405]
2022/03/09

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2022/02/16

重要事件披露

8-K - Current report
2022/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals